Anocca Doses First Patients in VIDAR-1 Trial of ANOC-001 TCR-T Therapy for KRAS-Mutated Pancreatic Cancer
Anocca AB, a clinical-stage biotechnology company focused on the development of advanced T-cell immunotherapies, has announced a major milestone in its clinical development efforts with the successful dosing of the first patients in the VIDAR-1 clinical program. The patients received ANOC-001, the company’s investigational T cell receptor-modified T-cell therapy (TCR-T) designed to target KRAS G12V mutations in pancreatic ductal adenocarcinoma (PDAC), one of the most aggressive and difficult-to-treat forms of cancer.
The achievement marks the first time ANOC-001 has been administered to patients and represents a significant step forward for Anocca’s efforts to develop highly targeted cell therapies for solid tumors. The program also highlights the company’s commitment to advancing next-generation non-viral gene-edited T-cell therapies, a rapidly emerging field within cancer immunotherapy.
A New Approach to Treating Pancreatic Cancer
Pancreatic cancer remains one of the most challenging cancers to treat and continues to be associated with poor patient outcomes worldwide. Among the various forms of the disease, pancreatic ductal adenocarcinoma is the most common and accounts for the vast majority of pancreatic cancer diagnoses.
Despite advances in cancer treatment, survival rates for pancreatic cancer remain alarmingly low. Many patients are diagnosed only after the disease has reached an advanced stage, limiting the effectiveness of conventional treatment approaches such as surgery, chemotherapy, and radiation therapy.
Current statistics indicate that the five-year survival rate for pancreatic cancer remains below 10%, making it one of the deadliest malignancies. For patients whose disease progresses despite standard treatment, therapeutic options are extremely limited.
This significant unmet medical need has driven researchers to explore innovative treatment approaches capable of targeting the underlying molecular drivers of the disease.
Anocca’s ANOC-001 therapy represents one such effort, leveraging the body’s immune system to identify and destroy cancer cells carrying specific genetic mutations.
Targeting KRAS Mutations
The focus of the ANOC-001 program is the KRAS G12V mutation, one of the most important genetic alterations associated with pancreatic cancer.
KRAS mutations are among the most frequently observed cancer-driving mutations across multiple tumor types, including pancreatic, colorectal, and lung cancers. These mutations play a critical role in promoting tumor growth, survival, and resistance to treatment.
In pancreatic cancer specifically, KRAS mutations are present in approximately 90% of patients, making them an attractive target for therapeutic intervention.
Among these mutations, KRAS G12V and KRAS G12D are particularly common and contribute significantly to disease progression.
Because KRAS mutations are directly involved in driving tumor biology, therapies capable of selectively targeting these abnormalities have long been viewed as a promising strategy in oncology. However, developing effective treatments against KRAS-mutated cancers has historically proven difficult.
ANOC-001 has been designed to overcome this challenge by directing engineered immune cells against cancer cells expressing the KRAS G12V mutation.
How ANOC-001 Works
ANOC-001 belongs to a class of therapies known as T cell receptor-modified T-cell therapies, or TCR-T therapies.
Unlike traditional cancer treatments that rely on chemotherapy or radiation to kill rapidly dividing cells, TCR-T therapies harness a patient’s own immune system to recognize and eliminate cancer cells.
The process involves engineering T cells with specialized receptors capable of identifying specific molecular targets present on tumor cells. Once infused back into the patient, these modified immune cells can seek out and attack cancer cells carrying the target mutation.
In the case of ANOC-001, the engineered T cells are designed to recognize and respond to cancer cells expressing the KRAS G12V mutation.
This highly targeted approach aims to improve treatment precision while potentially reducing damage to healthy tissues.
The therapy was discovered, developed, and manufactured entirely within Anocca’s facilities in Sweden, demonstrating the company’s integrated capabilities across research, development, and manufacturing.
First Non-Viral Gene-Edited T-Cell Therapy Evaluated in Europe
A notable aspect of the ANOC-001 program is its use of non-viral gene-editing technology.
Traditional cell therapies often rely on viral vectors to introduce genetic modifications into immune cells. While effective, viral manufacturing processes can be complex, costly, and difficult to scale.
Anocca has adopted a non-viral gene-editing approach that offers potential advantages in manufacturing efficiency, scalability, and product consistency.
According to the company, ANOC-001 is the first non-viral gene-edited T-cell therapy to enter clinical evaluation in Europe.
The technology is expected to support broader deployment of personalized cell therapies while potentially simplifying future commercial manufacturing.
By reducing dependence on viral vectors, the platform may enable more efficient production processes and facilitate the development of multiple targeted therapies within the company’s broader pipeline.
Launching the VIDAR-1 Clinical Program
ANOC-001 serves as the first therapeutic candidate within Anocca’s VIDAR-1 clinical program, a multi-product initiative focused on targeting KRAS-driven pancreatic cancers.
The program has been designed to evaluate a series of TCR-T therapies directed against different KRAS mutations and human leukocyte antigen (HLA) combinations.
This strategy reflects the increasing emphasis on precision medicine, where treatments are tailored according to the unique genetic characteristics of individual patients and their tumors.
Rather than focusing on a single therapeutic product, VIDAR-1 is structured as a platform capable of evaluating multiple related T-cell therapies within a coordinated clinical framework.
ANOC-001 is the first candidate to enter clinical testing, but additional therapies targeting other KRAS mutation variants are expected to follow.
The approach could potentially expand access to TCR-T therapies for broader patient populations while addressing the genetic diversity observed among individuals with pancreatic cancer.
Leadership Highlights Clinical Milestone
Anocca’s leadership team described the first patient dosing as a major achievement for the company and a validation of its scientific and manufacturing capabilities.
Reagan Jarvis, Co-Founder and Chief Executive Officer of Anocca, emphasized that the milestone demonstrates the company’s ability to develop, manufacture, and deliver precision-engineered TCR-T therapies for clinical use.
He noted that ANOC-001 was developed using Anocca’s proprietary analytical platform, which enables researchers to identify cancer targets and discover, characterize, and engineer highly specific T-cell receptors.
Jarvis also acknowledged the contributions of the company’s employees, investors, collaborators, and clinical partners whose efforts helped bring the program to the clinical stage.
Building a Broader KRAS-Targeting Pipeline
Hugh Salter, Chief Scientific Officer of Anocca, highlighted the broader vision behind the VIDAR-1 program.
According to Salter, the study was intentionally designed to support the evaluation of multiple TCR-T products targeting different KRAS mutations and HLA profiles.
He explained that ANOC-001 is only the first product candidate within the program and that additional therapies targeting other forms of mutant KRAS are expected to be introduced as development progresses.
Salter also emphasized the importance of the company’s non-viral gene-editing platform, which he believes will support the scalable delivery of highly precise cancer therapies to larger groups of patients in the future.
He expressed appreciation to clinical collaborators, trial participants, and their families for supporting the advancement of the program.
International Clinical Trial Underway
Patient recruitment and manufacturing activities are continuing as part of the Phase I portion of the VIDAR-1 study.
The trial is being conducted across eight leading university hospitals located in Sweden, Denmark, Germany, and the Netherlands, reflecting a broad European collaboration focused on advancing innovative cancer therapies.
The multicenter design will allow researchers to gather important safety, feasibility, and early efficacy data across a diverse patient population.
As enrollment progresses, investigators will evaluate how ANOC-001 performs in patients with KRAS G12V-mutated pancreatic cancer and assess its potential role within the evolving landscape of cellular immunotherapy.
The successful dosing of the first patients with ANOC-001 marks a significant milestone not only for Anocca but also for the broader field of T-cell therapy development.
With pancreatic cancer continuing to present one of oncology’s greatest unmet needs, innovative approaches capable of targeting the disease’s genetic drivers are urgently required. By combining precision T-cell engineering with non-viral gene-editing technology, Anocca aims to create a new generation of personalized cancer treatments capable of addressing mutations that have historically been difficult to target.
As the VIDAR-1 trial advances, the data generated from ANOC-001 and future KRAS-targeted candidates could help shape the next chapter in immuno-oncology, offering new hope for patients facing one of the most aggressive and deadly forms of cancer.
About Anocca
Anocca is a fully integrated clinical-stage biopharmaceutical company that develops libraries of T-cell receptor-modified T cell therapies (TCR-T) to redefine the treatment of solid tumours and other difficult to treat diseases, including infectious and autoimmune diseases. The company has built a unique discovery engine that uses programmable human cells to recreate and manipulate T cell immunity.
These proprietary technologies enable scaling of TCR-T cell therapy development, allowing the systematic generation of libraries of products that represent personalised treatments for the broad patient populations. Anocca currently has the broadest pipeline of TCR-T oncology cell therapy treatments.
Anocca operates an advanced research and development infrastructure, underpinned by a custom software ecosystem, AnoccaOS, and an in-house cGMP manufacturing and process development facility. Anocca’s TCR-T cell therapies are novel discoveries from its platform and manufactured using non-viral gene editing technology at Anocca’s facilities in Södertälje, Sweden. 130+ staff from 40+ nations work at Anocca.
About the VIDAR-1 clinical programme
VIDAR-1 is designed as a multi-product umbrella trial targeting oncogenic driver mutations in KRAS within pancreatic ductal adenocarcinoma (PDAC). It will investigate up to 20 patients per product in a set of phase I/II studies. Phase I is currently conducted at eight sites in four countries with additional countries and sites in phase II.Patients will be eligible to enrol if they have an HLA (i.e., genetic marker), and KRAS mutation, matching an available product.
